{"id":8659,"date":"2020-03-11T16:13:13","date_gmt":"2020-03-11T10:43:13","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=8659"},"modified":"2022-08-16T10:14:53","modified_gmt":"2022-08-16T04:44:53","slug":"recent-pharma-happenings-for-arkin-mastercard-gatesfoundation-wellcome","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-arkin-mastercard-gatesfoundation-wellcome","title":{"rendered":"Ofev\u2019s expanded use; Arkin Bio-Ventures II launch; USD 125 M for COVID-19 treatment"},"content":{"rendered":"\n

Boehringer Ingelheim\u2019s Ofev (nintedanib) has received FDA recommendation for the treatment of chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype<\/strong><\/h2>\n\n\n\n

Interstitial Lung Disease<\/a> – ILD \u2013 a group of a large number of lung disorders resulting in scarring or fibrosis of lungs<\/a>, caused by conditions such as autoimmune ILD, hypersensitivity pneumonitis and idiopathic nonspecific interstitial pneumonia. Referred to a group of more than 100 lung disorders, chronic fibrosing Interstitial lung disease is characterized by inflammation and lung scarring, making it hard for lungs to receive enough oxygen.  <\/p>\n\n\n\n

The first-ever drug Ofev is an oral treatment, already approved for the patients suffering from Idiopathic pulmonary fibrosis (IPF),<\/a> and extended for systemic sclerosis-associated interstitial lung disease (SSc-ILD). Moreover, the drug is under trials for treating different forms of cancers such as non-small cell lung cancer<\/a>, ovarian cancer<\/a>, and colorectal cancer<\/a>.<\/p>\n\n\n\n

The company, besides hosting a number of trials to test its product, is also partnering with other pharma companies to target fibrotic diseases.  Recently, Boehringer has acquired with Enleofen\u2019s preclinical interleukin-11 (IL-11) platform to develop first-in-class therapies for a spectrum of fibrotic diseases. <\/p>\n\n\n\n

Arkin Holdings has launched Arkin Bio-Ventures II \u2013 a new Life science investment fund, raising USD 140 Million<\/strong><\/h2>\n\n\n\n

The fund is supported by Arkin Holdings itself, along with two of the largest institutional investors comprising Migdal and Phoenix Group.<\/p>\n\n\n\n

An Israel-based Life Science investment company, Arkin plans to support pharma and biotech companies developing therapies that have high unmet needs. However, the major focus of the investment company would be in advancing gene therapy, RNA\/DNA-based therapy, and targeted therapies for a variety of indications. <\/p>\n\n\n\n

The company is planning to invest in pharma companies based in Israel and the US. <\/p>\n\n\n\n

Three charities – The Bill & Melinda Gates Foundation, the UK\u2019s Wellcome Trust, and the Mastercard Impact Fund \u2013 have pledged USD 125 M to fuel COVID-19 treatments<\/a><\/strong><\/h2>\n\n\n\n

The individual contribution of each of the trust is USD 50 M each for the Gates Foundation and the Wellcome Trust, whereas for the Mastercard Impact Fund it is USD 25 Million. <\/p>\n\n\n\n

The initiative COVID<\/a>-19 <\/a>Therapeutics Accelerator \u2013 <\/strong>is aiming to kickstart the process of development of drugs to target SARS-CoV-2, and is a part of USD 100 M commitment by the Gates Foundation announced in February 2020.<\/p>\n\n\n\n

The initial aim of the conjoint initiative would be to test already present antiviral drugs, compounds from J&J, Calibr, the drug research division of the Scripps Institute, and other biopharma companies, which are around 20,000-30,000 in number. The testing and screening would be undertaken by the Rega Institute in Belgium. <\/p>\n\n\n\n

In addition to this, the funds would be utilized in scaling up the manufacturing process of the drugs. <\/p>\n","protected":false},"excerpt":{"rendered":"

Boehringer Ingelheim\u2019s Ofev (nintedanib) has received FDA recommendation for the treatment of chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype Interstitial Lung Disease – ILD \u2013 a group of a large number of lung disorders resulting in scarring or fibrosis of lungs, caused by conditions such as autoimmune ILD, hypersensitivity pneumonitis and idiopathic […]<\/p>\n","protected":false},"author":1,"featured_media":8660,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[18119,1442,18120,17289,174,12514,651,16392,349,6733,17771,444,639,11652],"industry":[17225],"therapeutic_areas":[17242],"class_list":["post-8659","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-arkin-bio-ventures-ii","tag-arkin-holdings","tag-bill-and-melinda-gates-foundation","tag-boehringer-ingelheim","tag-colorectal-cancer","tag-covid-19-treatment","tag-idiopathic-pulmonary-fibrosis","tag-interstitial-lung-disease","tag-latest-pharma-news","tag-non-small-cell-lung-cancer","tag-ofev","tag-ovarian-cancer","tag-pharma-news","tag-recent","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases"],"acf":[],"yoast_head":"\nOfev nabs FDA nods; Arkin Bio-Ventures II launch; $ 125 M for COVID-19<\/title>\n<meta name=\"description\" content=\"The Bill & Melinda Gates Foundation, the UK\u2019s Wellcome Trust, and the Mastercard Impact Fund \u2013 have pledged $125 M to fuel COVID-19 treatments.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-arkin-mastercard-gatesfoundation-wellcome\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ofev nabs FDA nods; Arkin Bio-Ventures II launch; $ 125 M for COVID-19\" \/>\n<meta property=\"og:description\" content=\"The Bill & Melinda Gates Foundation, the UK\u2019s Wellcome Trust, and the Mastercard Impact Fund \u2013 have pledged $125 M to fuel COVID-19 treatments.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-arkin-mastercard-gatesfoundation-wellcome\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-03-11T10:43:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-08-16T04:44:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/11155400\/Pharma-news_11.03.2020.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ofev nabs FDA nods; Arkin Bio-Ventures II launch; $ 125 M for COVID-19","description":"The Bill & Melinda Gates Foundation, the UK\u2019s Wellcome Trust, and the Mastercard Impact Fund \u2013 have pledged $125 M to fuel COVID-19 treatments.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-arkin-mastercard-gatesfoundation-wellcome","og_locale":"en_US","og_type":"article","og_title":"Ofev nabs FDA nods; Arkin Bio-Ventures II launch; $ 125 M for COVID-19","og_description":"The Bill & Melinda Gates Foundation, the UK\u2019s Wellcome Trust, and the Mastercard Impact Fund \u2013 have pledged $125 M to fuel COVID-19 treatments.","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-arkin-mastercard-gatesfoundation-wellcome","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-03-11T10:43:13+00:00","article_modified_time":"2022-08-16T04:44:53+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/11155400\/Pharma-news_11.03.2020.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-arkin-mastercard-gatesfoundation-wellcome","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-arkin-mastercard-gatesfoundation-wellcome","name":"Ofev nabs FDA nods; Arkin Bio-Ventures II launch; $ 125 M for COVID-19","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-arkin-mastercard-gatesfoundation-wellcome#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-arkin-mastercard-gatesfoundation-wellcome#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/11155400\/Pharma-news_11.03.2020.jpg","datePublished":"2020-03-11T10:43:13+00:00","dateModified":"2022-08-16T04:44:53+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The Bill & Melinda Gates Foundation, the UK\u2019s Wellcome Trust, and the Mastercard Impact Fund \u2013 have pledged $125 M to fuel COVID-19 treatments.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-arkin-mastercard-gatesfoundation-wellcome"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-arkin-mastercard-gatesfoundation-wellcome#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/11155400\/Pharma-news_11.03.2020.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/11155400\/Pharma-news_11.03.2020.jpg","width":772,"height":482,"caption":"pharma news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/11155400\/Pharma-news_11.03.2020-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Arkin Bio-Ventures II<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Arkin Holdings<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bill And Melinda Gates Foundation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Boehringer Ingelheim<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Colorectal Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">COVID-19 Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Idiopathic Pulmonary Fibrosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Interstitial lung disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ofev<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ovarian Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Arkin Bio-Ventures II<\/span>","<span class=\"advgb-post-tax-term\">Arkin Holdings<\/span>","<span class=\"advgb-post-tax-term\">Bill And Melinda Gates Foundation<\/span>","<span class=\"advgb-post-tax-term\">Boehringer Ingelheim<\/span>","<span class=\"advgb-post-tax-term\">Colorectal Cancer<\/span>","<span class=\"advgb-post-tax-term\">COVID-19 Treatment<\/span>","<span class=\"advgb-post-tax-term\">Idiopathic Pulmonary Fibrosis<\/span>","<span class=\"advgb-post-tax-term\">Interstitial lung disease<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/span>","<span class=\"advgb-post-tax-term\">Ofev<\/span>","<span class=\"advgb-post-tax-term\">Ovarian Cancer<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Mar 11, 2020","modified":"Updated on Aug 16, 2022"},"absolute_dates_time":{"created":"Posted on Mar 11, 2020 4:13 pm","modified":"Updated on Aug 16, 2022 10:14 am"},"featured_img_caption":"pharma news","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=8659"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8659\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/8660"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=8659"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=8659"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=8659"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=8659"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=8659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}